Home / Community / News / News

News

03/13/2017 - 11:30am

A potentially revolutionary technology may allow development of a drug for DM that can correct a patient’s DNA by selectively removing the expanded CTG and CCTG repeats in DM1 and DM2, respectively.

02/24/2017 - 10:39am

Clinical trials involve substantial investments by drug developers, but especially by DM patients and families. Clinical trials proposed for our community must have adequate scientific rationale behind them.

02/24/2017 - 10:22am

MDF runs down some important changes in the purposes and rationale of NINDS funding mechanisms for postdoctoral fellows.

02/24/2017 - 9:59am

FDA released an online course to accompany their draft guidance on how to best communicate with the Agency in preparing and filing an IND.

02/24/2017 - 9:50am

Gene editing is a potential avenue for therapy development in DM. With the safety, efficacy and delivery challenges, how do we get there?

Partners

© Myotonic Dystrophy Foundation. All rights reserved.